• Regulatory clarity: ATF Ruling 2026-2, effective July 2, 2026, classified the BolaWrap(R) 150 as a federally recognized instrument of restraint rather than a firearm or “any other weapon” — which may remove longstanding procurement barriers across law enforcement, corrections, and government markets and is helping agencies move from extended evaluation toward department-wide programs.
• Counter-drone sensing: A strategic transaction with Israeli AI sensing company Frenel Imaging Ltd. gives WRAP exclusive U.S. and NATO distribution rights to Division of Focal Plane (“DoFP”) polarimetric sensing technology, which detects drones by their physical light-scattering signatures rather than radio-frequency emissions — enabling detection, the company says, even after a drone stops transmitting. WRAP describes it as the detection layer of its emerging WrapShield(TM) platform.
• A three-part response layer: With the first operational Wraptor MX(TM) prototype and an early-adopter program, WRAP is positioning a three-component Non-Lethal Response(TM) architecture — BolaWrap(R) 150 (handheld restraint), Wraptor MX(TM) (multi-shot platform), and the developing DFR-X(TM) (drone-deployed restraint) — around a common operating framework.

For the agencies adopting them, non-lethal tools share a single measure of success: a tense encounter that ends with everyone going home safely — the person in crisis, the officer responding, and the community watching. That standard sits at the center of Wrap Technologies (NASDAQ: WRAP) pitch to public safety buyers, and the company is now expanding the range of situations its platform is built to address.

Wrap Technologies entered the third quarter of 2026 reporting continued adoption of its Non-Lethal Response(TM) system across public safety agencies, alongside approximately $1.2 million in international orders and a reaffirmed target of roughly 100% year-over-year revenue growth in 2026, according to the company. WRAP also announced a strategic transaction with Israeli AI sensing company Frenel Imaging Ltd., acquiring exclusive U.S. and NATO distribution rights to physics-based polarimetric sensing technology that it says will underpin its emerging WrapShield(TM) counter-unmanned aircraft system (“UAS”) platform.

Taken together with the recent unveiling of the company’s Wraptor MX(TM) multi-shot restraint platform, the announcements point to both near-term commercial traction and a longer-term shift in how WRAP positions itself: less as a maker of a single device and more as a provider of an integrated system spanning restraint instruments, operational doctrine, sensing technology, and command-and-control — a platform the company says addresses several public safety and security markets at once.

The newly reported orders span two markets. In Brazil, distributors placed orders supporting deployments with multiple public safety agencies, while an additional order in India strengthens the company’s presence in one of the world’s largest public safety markets. WRAP says much of the activity reflects repeat customer demand, which it characterizes as a sign that agencies are moving beyond initial evaluation toward broader operational use. The company reports its Non-Lethal Response(TM) system has been validated by more than 1,000 agencies across 60+ countries, with headquarters in Miami, Florida and manufacturing in Norton, Virginia.

“We are entering the third quarter with meaningful commercial momentum already in place,” said Scot Cohen, Chief Executive Officer of WRAP (ibn.fm/v4TtD). “Opening the quarter with significant international orders is encouraging on its own, but what matters more is what those orders represent — repeat customers expanding their deployments and new markets adopting our technology.”

The company also pointed to ATF Ruling 2026-2, effective July 2, 2026, issued by the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”), which classified the BolaWrap(R) 150 as an instrument of restraint rather than a firearm or “any other weapon.” WRAP’s management believes the decision clarifies a longstanding regulatory question that had complicated procurement in certain markets and expects it to support both domestic and international interest, though the commercial impact will play out over time. According to the company, some agencies that had kept the BolaWrap(R) 150 under extended evaluation are now moving to formal, department-wide Non-Lethal Response(TM) programs — pairing the instrument with WrapTactics(R) operational doctrine training. Management characterizes that shift, from device evaluation to institutional commitment, as its most significant domestic adoption signal since commercial launch, though independent confirmation of the pace of that conversion is not yet available.

While the BolaWrap(R) 150 remains the anchor of its commercial business, WRAP is broadening the WrapShield(TM) platform. Alongside the counter-drone sensing initiative, the company recently introduced the first operational prototype of WraptorMX(TM), a modular multi-shot restraint platform aimed at tactical teams, corrections, and perimeter security. According to WRAP, the prototype extends the platform’s non-lethal response layer beyond the handheld BolaWrap(R) 150 and complements a developing drone-deployed restraint system, DFR-X(TM), forming a family of proportionate response options built around a common operating architecture.

Through the Frenel Imaging transaction, WRAP acquired exclusive U.S. and NATO distribution rights to proprietary Division of Focal Plane (“DoFP”) polarimetric sensing technology, which the company says detects objects by their physical light-scattering signatures rather than their electronic emissions — enabling detection even after a drone stops transmitting. WRAP describes the technology as the detection layer of WrapShield(TM), an integrated platform intended to combine threat detection, AI-assisted decision support, and multiple non-lethal response options under a single operating architecture.

The move targets a growing problem for governments and security agencies. Consumer drones have become common tools for smuggling contraband into correctional facilities, conducting unauthorized surveillance, supporting cross-border criminal activity, and disrupting military installations and critical infrastructure. Traditional counter-drone systems often rely on radar or radio-frequency detection, which can leave gaps when drones operate autonomously or cease transmitting — a limitation the company argues its newly licensed sensing technology helps address. Independent validation of that capability in the field is not yet publicly available.

Collectively, the steps mark a measured evolution from a single-product provider toward an integrated public safety platform. The BolaWrap(R) 150 remains the commercial foundation; Wraptor MX(TM) broadens response options for multi-engagement scenarios; and DFR-X(TM) would extend those capabilities to drone-based deployment. Combined with WrapShield(TM)’s AI-enabled sensing and command architecture, WRAP is assembling a layered system meant to help agencies detect, assess, and respond to evolving threats using proportionate, non-lethal options.

As governments continue investing in officer safety and modern public safety technology, WRAP is positioning across several complementary markets rather than relying on a single product. Whether that breadth translates into sustained growth will depend on execution, the pace of agency adoption, and how quickly the newer platforms move from prototype to deployment. As Cohen put it, management believes the developments reinforce its conviction that WRAP is building “a differentiated public safety technology platform positioned for long-term growth.”

For more information, visit the company’s website at wrap.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

About / Disclaimer

This article was produced by IBN Editorial Staff and is intended for informational purposes only. It is not investment advice and should not be relied upon as the basis for any investment decision. Statements attributed to Wrap Technologies Inc. or its management, including any forward-looking statements regarding revenue growth, product development, or market opportunities, reflect the company’s views and are subject to risks and uncertainties; actual results may differ materially. Readers should conduct their own due diligence and consult a qualified professional. Additional company information is available at wrap.com.

• The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer.
• The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development.
• VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
• Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program.
• Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward human clinical trials (https://ibn.fm/fc9tP).

Dr. Erkel brings approximately two decades of experience in antibody engineering, immuno-oncology research and preclinical drug development. Before joining VERAXA, he led therapeutic research programs at MorphoSys AG, where he worked on conditionally active T-cell engagers and other antibody-based therapies prior to the company’s acquisition by Novartis. His career has also included leadership positions in antibody engineering and molecular biology, spanning both scientific discovery and candidate development.

The appointment reflects a broader phase of development for VERAXA as it seeks to translate laboratory research into clinical-stage oncology programs. The company’s strategy centers on antibody therapeutics designed to improve the precision of cancer treatment. While traditional immunotherapies have transformed oncology, researchers continue searching for approaches that preserve anti-tumor activity while minimizing damage to healthy tissue.

VERAXA’s lead development program is built around its proprietary BiTAC(R)-TCE technology, a conditionally active bispecific T-cell engager designed to recognize two tumor-associated markers before activating an immune response. Management believes this dual-targeting approach may improve selectivity by directing immune cells primarily toward cancer cells expressing both markers, potentially reducing activity against healthy cells displaying only one target.

Earlier this month, the company also announced encouraging regulatory progress after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute, which supported the biological rationale and proposed non-clinical development strategy for its lead BiTAC(R)-TCE candidate. The feedback provided additional clarity as the program advances toward future regulatory submissions.

Initial preclinical findings presented at the American Association for Cancer Research (“AACR”) Annual Meeting in April demonstrated that the company’s lead candidate selectively attacked cancer cells expressing both target molecules while sparing cells expressing only one marker. According to VERAXA, those studies also indicated efficacy comparable to conventional T-cell engagers while suggesting the potential for an improved therapeutic index if confirmed in future development.

Questions Investors May Be Asking About BiTAC(R)

What makes BiTAC(R) different from conventional T-cell engagers?

Traditional T-cell engagers generally activate immune cells whenever a single target is detected, which can increase the risk of attacking healthy tissues that also express that marker. VERAXA’s BiTAC(R) technology is designed to require recognition of two tumor-associated targets before triggering immune-cell activation, an approach intended to increase selectivity and potentially improve safety. A conditionally active T-cell binding CD3 domain adds another layer of safety control to BiTAC-TCEs.

Why is there continued demand for new T-cell engager technologies?

Although T-cell engagers have become an important area of cancer drug development, many researchers continue working to reduce treatment-related toxicity while expanding their use against solid tumors. Technologies that improve targeting precision could broaden the range of patients who may benefit from these therapies if clinical results support the approach.

Where do antibody-drug conjugates (“ADCs”) fit into VERAXA’s strategy?

Beyond BiTAC(R), VERAXA is developing a broader pipeline that includes other bispecific antibody-drug conjugate formats. ADCs combine antibodies with potent therapeutic payloads that are delivered directly to cancer cells, while bispecific formats seek to further improve targeting by recognizing multiple biomarkers simultaneously. Together, these platforms provide multiple development opportunities across different cancer indications.

VERAXA’s broader strategy extends beyond a single product candidate. The company is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific antibody-drug conjugates and additional engineered antibody formats designed for solid tumors and other cancer types.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

• The company has appointed Alec Rossa as Chief Revenue Officer to lead commercialization, strategic partnerships, and deployment of the company’s planned Power-as-a-Service (“PaaS”) business model.
• Management says early commercial opportunities include AI data centers, industrial facilities, defense applications and other energy-intensive infrastructure.
• The company is pursuing a strategy that combines technology development, intellectual property protection and recurring revenue through long-term Power-as-a-Service agreements.
• American Fusion(TM) recently highlighted progress on its Texas Tech University testing program, following regulatory authorization covering all twelve Texatron(TM) Fusion Engine(TM) research systems.
• American Fusion(TM) has also expanded its intellectual property portfolio to 76 U.S. patent applications, moving toward its long-term objective of filing more than 260 patent applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has strengthened its commercial leadership with the appointment of Alec Rossa as Chief Revenue Officer, a move that reflects the company’s increasing focus on preparing its fusion technology platform for future commercialization alongside ongoing engineering and testing activities.

The announcement, made on July 22, assigns Rossa responsibility for leading American Fusion’s(TM) global commercial strategy, including customer development, government and institutional relationships, strategic partnerships and deployment planning for the company’s proposed Power-as-a-Service (“PaaS”) model (https://ibn.fm/vyobC).

Rossa brings nearly two decades of executive leadership experience from MD Charlton Ltd., where he served as President and Chief Executive Officer of one of Canada’s largest distributors of police and tactical equipment. During that period, he developed relationships with military organizations, law enforcement agencies, emergency response organizations and government procurement departments while overseeing complex commercial agreements and institutional sales programs.

For American Fusion(TM), those relationships align with management’s view that future demand for advanced power generation could extend beyond commercial utilities into government, defense and critical infrastructure markets.

The company’s long-term business strategy differs from a traditional equipment sales model. Rather than simply manufacturing reactors for customers, American Fusion(TM) intends to own, operate and maintain Texatron(TM) Fusion Engine(TM) systems while selling electricity through long-term Power-as-a-Service agreements. Management believes that approach could allow customers to access reliable baseload power without making large upfront capital investments while creating recurring revenue opportunities for the company over the operational life of installed systems.

The commercial appointment comes as American Fusion(TM) continues advancing the engineering program supporting its proprietary fusion platform.

In a recent interview summarized by the company, Executive Chairman Brent Nelson outlined several operational milestones, including progress following receipt of certification from the Texas Department of State Health Services (“DSHS”) that authorizes research involving all twelve registered Texatron(TM) Fusion Engine(TM) models at Texas Tech University (https://ibn.fm/g8G2D).

According to Nelson, the certification allows the company to proceed with the next phase of testing after months of regulatory preparation. Testing activities at Texas Tech University are expected to focus initially on validating fusion reactions within the Texatron(TM) platform while collecting engineering data on plasma behavior, operating performance and electrical characteristics.

Management has outlined a staged testing roadmap that includes verification of fusion reactions, measurement of plasma temperature and density, evaluation of pulse-generated electrical output and continued progress toward sustained electricity generation. The company has also stated that data generated during testing is expected to be independently documented, with findings potentially available for publication following appropriate review.

Scientific engagement remains another component of the development strategy.

American Fusion(TM) recently announced that Chief Technology Officer Dr. John Brandenburg would present the Texatron(TM) Fusion Engine(TM) platform at a particle physics conference hosted by Fermi National Accelerator Laboratory (Fermilab), providing an opportunity to discuss the technology with researchers working across particle physics, plasma science and related disciplines.

Management has emphasized that independent scientific evaluation will play an important role as the company advances through successive engineering milestones.

Commercial planning is also becoming more defined. During the executive interview, Nelson identified AI and hyperscale data centers among the company’s most immediate target markets, citing rapidly growing electricity demand driven by artificial intelligence infrastructure. Additional markets identified by management include industrial facilities, mining operations, defense installations, strategic infrastructure and longer-term space applications.

The addition of a Chief Revenue Officer reflects the company’s intention to begin developing commercial relationships well before technology deployment reaches later stages of maturity.

Alongside commercialization efforts, American Fusion(TM) continues expanding what management views as another long-term corporate asset: its intellectual property portfolio. On July 23, the company announced the filing of 19 additional U.S. patent applications, bringing its total to 76 filed applications while maintaining a stated objective of eventually filing more than 260 patents covering the Texatron(TM) platform and related technologies (https://ibn.fm/ah5Oz).

The latest filings span reactor architecture, plasma confinement, electromagnetic systems, fuel delivery, reactor control and power management technologies, reflecting the company’s strategy of protecting multiple components of its broader engineering platform rather than individual reactor designs alone. American Fusion(TM) has indicated that protecting those innovations remains a central element of its long-term business model.

At the same time, engineering teams have continued preparing the testing environment at Texas Tech University through installation and calibration of vacuum systems, diagnostic instrumentation, electronics, remote switching equipment and data acquisition systems needed for the next phase of technical evaluation.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization.
• Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair.
• GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes.

Cartilage Regeneration Gains Strategic Validation

The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated growing strategic interest among major orthopedic companies in regenerative approaches designed to improve joint repair outcomes and expand treatment options for patients suffering from cartilage defects.

This activity provides important context for Regentis as it develops next-generation cartilage repair solutions. As established medical technology companies continue seeking differentiated platforms capable of addressing significant unmet needs in orthopedics, GelrinC’s off-the-shelf, cell-free profile and practical surgical workflow position it within a market segment increasingly recognized for both clinical and strategic commercial value.

Regentis Advances GelrinC Toward Multiple Milestones

Within this evolving market landscape, Regentis Biomaterials (NYSE American: RGNT) is advancing GelrinC, its proprietary hydrogel-based cartilage regeneration platform designed to provide an off-the-shelf, cell-free solution for cartilage repair. Unlike traditional approaches that may require cell harvesting, laboratory expansion, or more complex treatment workflows, GelrinC is designed to be administered through a streamlined single-step surgical procedure while supporting tissue regeneration.

The company is advancing on several important clinical, regulatory, commercial, and manufacturing fronts. Key priorities include continued enrollment in its U.S. clinical study, preparation for a Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”), ongoing commercialization activities in Europe, and continued manufacturing optimization to support product consistency, scalability, and broader adoption.

Building a Foundation for Commercial Scale

Beyond clinical advancement, Regentis is building the infrastructure required to support commercial adoption. In Europe, where GelrinC has already secured CE Mark approval, the company has moved from development planning into commercial activities, including hands-on surgeon training, Centers of Excellence engagement, market education, and discussions with potential distribution partners.

This commercial readiness addresses many of the practical requirements for adoption in orthopedic markets. Surgeons need familiarity with the implantation procedure, hospitals need products that fit existing operating room workflows, and commercial partners need confidence that the product can be supplied consistently and on a scale.

Regentis’ continued focus on manufacturing optimization and product consistency supports this broader commercialization strategy. For a cell-free, off-the-shelf product such as GelrinC, scalable manufacturing is not only a technical requirement – it is a key commercial advantage compared with more complex cell-based therapies that require patient-specific harvesting, processing, and reimplantation.

A Potentially Transformative Approach to Cartilage Repair

GelrinC represents Regentis’ effort to address limitations associated with existing cartilage repair procedures by providing a biomaterial-based platform designed to support durable cartilage regeneration while simplifying treatment. With CE Mark approval already secured in Europe, commercialization activities underway, and multiple development milestones ahead in the United States, the company has reached an important stage in its transition from clinical development toward broader commercialization.

As strategic acquisitions continue to underscore the value of cartilage regeneration technologies, Regentis’ progress across clinical, regulatory, manufacturing, and commercial initiatives could provide investors with increasing visibility into GelrinC’s long-term commercial potential and the broader opportunity within regenerative orthopedics.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• Drones play a crucial role in modern military operations, but it’s becoming increasingly more important for these drones to operate without relying on GPS, due to the prevalence of jamming and other issues.
• Growing demand for GPS-independent drone navigation has prompted companies such as Robotto to pivot their technologies toward defense applications.
• Another company operating in this expanding market is SPARC AI, which develops GPS-free target acquisition and autonomous navigation software for drones and other edge devices.

Few technologies have reshaped modern warfare as dramatically as unmanned aerial systems (“drones”). They provide real-time battlefield intelligence, logistical support and precision capabilities while keeping personnel farther from danger. Compared with many traditional military platforms, drones also offer a relatively low-cost solution that can be deployed at scale.

However, as electronic warfare becomes more sophisticated, it is no longer enough simply to deploy drones, they must also be capable of operating without GPS.

The reason is simple: electronic warfare has become a defining feature of modern conflict. GPS jamming overwhelms legitimate satellite signals, while GPS spoofing transmits false positioning data intended to mislead navigation systems. Both tactics can severely limit the effectiveness of conventional drones.

Both jamming and spoofing are frequently used in war, so if your drones aren’t capable of operating in compromised zones or signal-contested areas, they may not be nearly as useful as they could be. As a result, drones that rely exclusively on satellite navigation can lose effectiveness in contested environments, increasing demand for alternative navigation and targeting technologies.

Because of the growing importance of GPS-free navigation in war and the demand for drones equipped with these capabilities, some companies are shifting and have shifted to support this growing industry.

One example is Robotto, a Danish startup that originally developed drone software for wildfire detection and forest mapping. Following Russia’s invasion of Ukraine, the company adapted its technology for GPS-independent military targeting after being approached by a former Danish Army colleague. Today, its software has reportedly been deployed on more than 5,000 drones supporting “find, fix, finish” missions in Ukraine.

Another company positioned to benefit from this evolving defense landscape is SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF). The company develops next-generation GPS-free target acquisition and autonomous navigation software for drones and other edge devices.

SPARC AI’s software-only platform uses zero-signature technology to provide real-time detection, tracking and behavioral analysis without relying on radar, lidar or other sensor-heavy hardware. The company’s objective is to combine mathematics, artificial intelligence and edge computing into a unified intelligence platform.

Built on more than 15 years of research and development, SPARC AI’s Target Acquisition System geolocates visible objects using camera telemetry data. By constructing a three-dimensional understanding of terrain and position, the platform is designed to deliver GPS-level accuracy without emitting detectable signals.

Essentially, it constructs a 3D understanding of terrain and position, which can help achieve GPS-level accuracy in a zero-signature configuration. The platform also supports terrain-based navigation using proprietary AI models and XYZ orientation, enabling operation in environments where satellite signals are denied or degraded.

Purpose-built for Denied, Degraded, Intermittent and Limited (“DDIL”) environments, the software requires no additional hardware or costly external sensors, helping reduce both power consumption and operating costs.

As military organizations increasingly prioritize resilient autonomous systems capable of operating in electronically contested environments, GPS-independent navigation is becoming a strategic necessity rather than a niche capability. Companies developing software-first solutions designed for these conditions, including SPARC AI, may be well positioned as governments continue investing in next-generation defense technologies.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

• Geographically part of the Solomon Islands archipelago, Bougainville has been politically linked to Papua New Guinea since the colonial era.
• One of the central questions surrounding Bougainville’s independence is economic viability.
• Numa Numa is working with landowner groups and local stakeholders to advance mining opportunities while respecting Bougainville’s legal framework and customary ownership systems.

For Bougainville, the path to independence is about more than politics. It is also about economics. As the autonomous Pacific region continues discussions regarding its future political status, the development of its vast mineral resources has emerged as one of the most important factors in determining whether an independent Bougainville can build a sustainable and prosperous economy. Numa Numa Resources is among the companies seeking to help unlock that potential through partnerships with landowners and infrastructure development tied to some of the region’s most significant mineral assets.

Bougainville occupies a unique place in the Pacific. Although geographically part of the Solomon Islands archipelago, it has been politically linked to Papua New Guinea since the colonial era. Following Papua New Guinea’s independence in 1975, tensions in Bougainville increasingly centered on questions of political representation, economic participation and the management of natural resources. Those tensions were amplified by the presence of the Panguna Mine, one of the world’s largest copper and gold operations during its years of production.

The Panguna Mine began production in 1972 and quickly became an economic powerhouse. At its peak, it generated as much as 45% of Papua New Guinea’s export revenue. While the mine created substantial wealth, many Bougainvilleans felt that local communities received an inadequate share of the economic benefits while bearing the environmental and social impacts associated with mining activities.

These grievances became one of several factors that contributed to the Bougainville conflict, known as “the Crisis,” which lasted from 1988 to 1998 and resulted in the closure of the Panguna Mine. The conflict ultimately led to the Bougainville Peace Agreement in 2001, which established a framework for autonomy and future political consultations regarding Bougainville’s status. The agreement created the autonomous Bougainville government and provided a pathway for a referendum on independence.

That referendum took place in 2019. According to official results reported by the Bougainville Referendum Commission and documented by international observers, 97.7% of voters chose independence over continued autonomy within Papua New Guinea. While the referendum was nonbinding and final implementation remains subject to negotiations between Bougainville and Papua New Guinea, the result demonstrated overwhelming public support for self-government.

One of the central questions surrounding independence is economic viability. Any newly independent nation must generate sufficient revenue to fund government services, infrastructure, healthcare, education and economic development. For Bougainville, mineral resources represent one of the most significant potential sources of future revenue.

The importance of copper in particular has increased in recent years as electrification and renewable energy deployment drive demand for the metal. The International Energy Agency has identified copper as one of the critical minerals essential to energy transition technologies, including electric vehicles, power grids and renewable generation systems. This global demand has renewed interest in major undeveloped copper deposits around the world, including those located in Bougainville.

As discussions about Bougainville’s future continue, many observers view resource development as a key component of any long-term economic strategy. The challenge is ensuring that future projects are developed differently than they were in the past. Lessons from the Panguna experience have highlighted the importance of local participation, transparent governance, environmental stewardship and meaningful benefit-sharing arrangements with customary landowners.

This is where Numa Numa Resources has positioned itself. Numa Numa is working with landowner groups and local stakeholders to advance mining opportunities while respecting Bougainville’s legal framework and customary ownership systems. The company’s strategy emphasizes collaboration with resource owners and community engagement as part of the development process.

Numa Numa is also investing in infrastructure designed to support long-term economic development. The company reports that it is constructing the first east-west road across Bougainville’s mountainous central mining district since before the civil conflict. Such infrastructure can provide benefits that extend beyond resource extraction by improving transportation access, facilitating commerce and connecting isolated communities.

In addition, Numa Numa has entered into agreements with landowners associated with areas surrounding the Panguna resource district. The company has stated that these agreements support development efforts connected to an estimated $100 billion copper and gold resource opportunity within the region. While the ultimate value of any mineral deposit depends on numerous technical and economic factors, the scale of the resource illustrates why mining remains central to conversations about Bougainville’s future.

For Bougainville, independence and economic development are closely linked. The region possesses significant natural resources, a population that has expressed strong support for self-government and a growing focus on rebuilding infrastructure and institutions. Whether independence ultimately becomes a reality will depend on political negotiations, but many believe that responsible resource development will play a critical role in shaping the region’s long-term prospects.

Numa Numa Resources is operating at the intersection of those ambitions. By working with landowners, supporting infrastructure projects and pursuing opportunities tied to Bougainville’s mineral wealth, the company is participating in a broader effort to help create the economic foundation that many supporters view as essential to Bougainville’s future.

For more information, visit www.NumaNumaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to Numa Numa are available in the company’s newsroom at https://ibn.fm/NUMA

• Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine, clinical support, and fulfilment
• RxCompoundStore and Mister Meds are licensed compounding pharmacies, which produce custom medications that are supplied wholesale to independent clinics and directly to consumers through ETST’s other subsidiary, Peaks Curative LLC
• The subsidiaries create a dual-market operation that reduces reliance on one market segment and continues to contribute to Earth Science Tech’s cash-flow-driven and dilution-free growth
• In fiscal year 2026, Earth Science Tech reduced its total liabilities and increased its total assets, resulting in a net increase in shareholder equity

Earth Science Tech (OTC: ETST), a diversified holding company, is building a healthcare platform that vertically integrates various aspects of patient care, from consultation to fulfillment. The company achieves this through the synergy of its specialized subsidiaries RxCompoundStore (“RxCS”), Mister Meds, and Peaks Curative LLC.

RxCS is a Miami-based licensed compounding pharmacy that provides sterile and non-sterile medications. Mister Meds, on the other hand, is an Abilene-based compounding pharmacy that provides sterile medication and handles hazardous drugs. RxCS and Mister Meds compound ingredients, creating custom medications that they then supply wholesale to independent clinics. 

The company’s third subsidiary, Peaks Curative (“Peaks”), targets the B2C segment. Peaks is a telemedicine referral platform that offers asynchronous consultations for compounded medications prepared by RxCS and Mister Meds. Peaks enables patients to explore various treatment options for weight loss, hair growth, and men and women’s sexual health. Additionally, the platform connects patients to licensed medical providers who review duly filled online questionnaires describing the patients’ unique needs before approving medications. Peaks then fulfills the orders, meaning it commercially sells medications directly to consumers. 

By targeting both B2B and B2C segments and integrating digital (telemedicine) and physical manufacturing operations, Earth Science Tech has created a dual-revenue, omnichannel business that has continued to contribute to growth. For instance, the company reported revenues of $35.7 million in the financial year ended March 31, 2026 (“FY2026”), up from $33.1 million in FY2025 and $11.95 million in FY2024 (https://ibn.fm/obdbw).

“In fiscal 2026, we grew revenue, increased earnings, generated positive operating cash flow and strengthened our balance sheet, all without adding debt to our balance sheet,” said Giorgio R. Saumat, CEO and Chairman of the Board (https://ibn.fm/xfmEq).

In addition, according to the FY2026 annual report, Earth Science Tech repaid in full its long-term debt and had no outstanding short-term business loans as of the end of the fiscal year. A review of the balance sheet shows that the company reduced its total liabilities to $1.928 million in FY2026 from $3.146 million in FY2025 and increased its total assets to $8.969 million in FY2026 from $7.066 million in FY2025, reflecting an overall year-over-year increase in shareholder equity (https://ibn.fm/zOV93).

The company believes its current cash flow from operations will be sufficient to fund its anticipated operating and capital requirements for FY2027. And, according to the annual report, it does not anticipate needing to raise additional dilutive financing. This underscores Earth Science Tech’s cash-flow-driven and dilution-free growth. While many OTC companies rely on toxic financing or constant stock dilution to survive, ETST uses organic cash flow and realized asset gains to actively fund its operations, real estate expansions, and share repurchase program. 

As Earth Science Tech continues to seamlessly integrate patient care through its specialized subsidiaries, it is creating a business that is markedly different from other OTC stocks. Not only has the company logged year-over-year growth without saddling itself with debt or relying on toxic financing, but it has also created a dual-market business that does not solely rely on either consumers or businesses. These are hallmarks of a company focused on maximizing shareholder value.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• Pressure on agencies to adopt response-to-resistance alternatives has intensified, widening demand for tools that can control situations without injury or pain rather than provoke confrontations.
• Wrap has built its business around a Non-Lethal Response(TM) platform that converges remote restraint, training, and evidence management, spanning the BolaWrap(R) 150, Wrap Reality(TM), Wrap Vision(TM), Wrap Tactics(TM), and counter-drone solutions.
• With the July 2026 launch of WrapShield(TM) and an exclusive U.S. and NATO license to Frenel Imaging’s TPiCore(R) thermal-polarimetric sensing, Wrap is adding an AI-enabled detection layer, beginning with counter-UAS.

A Widening Market for Response-to-Resistance Technology

High-profile use-of-force incidents have driven costly litigation, strained community trust, and increased scrutiny of how officers are equipped and trained. That environment has pushed agencies toward tools that create time, distance, and tactical advantage, particularly in encounters involving individuals in mental- or behavioral-health crises and has widened the customer base beyond traditional policing into corrections, campus safety, healthcare, and transportation security. Wrap Technologies (NASDAQ: WRAP) built its business around closing the response-to-resistance gap with technology that reduces injury to everyone involved. 

The company describes itself as a global public safety technology provider developing policing solutions for law enforcement and security personnel across the United States, Europe, the Middle East, Africa and Asia Pacific. Its flagship BolaWrap(R) 150 Remote Restraint Device, along with a growing portfolio of training and evidence-management tools, is designed to give officers options that reduce injury to everyone involved.

Independent market research points to growing investment in technologies designed to help law enforcement agencies manage critical incidents more safely and effectively. Fortune Business Insights estimates this segment will expand from approximately $1.94 billion in 2025 to about $3.25 billion by 2034, reflecting a compound annual growth rate of roughly 5.9% as agencies adopt more advanced AI-enabled, autonomous, and drone-supported capabilities. At the same time, MarketsandMarkets projects the global law enforcement software market will grow from about $20.25 billion in 2025 to nearly $33 billion by 2030.

BolaWrap(R) 150 and a Regulatory Milestone

The flagship BolaWrap(R) 150 is a patented, handheld device that discharges a Kevlar(R) tether to help officers gain control of a non-compliant individual from a distance of approximately 10 to 25 feet, pairing a multi-sensory distraction of sight and sound with remote physical restraint. It is not pain-based compliance — it does not shoot, strike, shock, or incapacitate — and is intended to help officers operate pre-escalation on the force continuum. In July 2026, the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”) issued a ruling classifying the BolaWrap(R) 150 as an instrument of restraint rather than a firearm or “any other weapon” under federal law, which the company believes removes regulatory uncertainty, may simplify procurement, and may expand adoption across corrections, healthcare, transportation, education, government, and private security. The BolaWrap(R) is used by over 1,000 agencies across the U.S. and in 60+ countries and is backed by IADLEST-certified training.

A Converged Non-Lethal Response(TM) Portfolio

Beyond the device, Wrap has built an integrated portfolio. Wrap Reality(TM) provides immersive VR training; Wrap Tactics(TM) delivers a policy-aligned digital training and certification system; and Wrap Vision(TM) — an all-new body-worn camera and cloud-based evidence platform built with IONODES and a made-in-America assembly roadmap — captures and manages digital evidence. Adoption increasingly takes the form of agency-wide programs that bundle hardware with recurring, subscription-based training, software, and policy support, including WrapPlus(TM) and managed services. Wrap has also extended its non-lethal principles into counter-unmanned aircraft systems (“C-UAS”) for defense and homeland-security customers, with next-generation solutions such as the 1KC Kinetic Anti-Drone Cassette, the patent-pending MERLIN-Interdictor drone-interdiction payload, and the Wraptor MX(TM) multi-shot platform.

WrapShield(TM) and Frenel’s TPiCore(R) Detection Technology

In July 2026, Wrap launched WrapShield(TM), an autonomous defense and public safety platform intended to serve as an operating layer that connects detection, decision, and response. Its three functions are Detect (advanced multi-modal sensing with AI edge processing), Orchestrate (AI-assisted, human-supervised threat classification and decision support that interoperates with government and third-party command-and-control), and Respond (integration of Wrap’s own and third-party capabilities based on mission requirements and rules of engagement). The initial application is counter-UAS.

The platform’s detection layer is anchored by a strategic investment in Frenel Imaging Ltd., an Israeli advanced-sensing company, and an exclusive U.S. and NATO license to Frenel’s proprietary TPiCore® thermal-polarimetric imaging. Where a conventional thermal camera reads a single dimension of infrared data — intensity — TPiCore(R) is designed to capture the polarization of thermal radiation at the pixel level, supporting reconstruction of an object’s physical characteristics and material composition. Wrap believes this “polarimetric fingerprint” cannot be spoofed, jammed, or turned off and requires no radio-frequency signal to detect — addressing a blind spot in the RF-based detection much of the counter-UAS market relies on. Frenel’s Division of Focal Plane architecture delivers simultaneous polarimetric and thermal data processed in real time on deployable edge hardware across drone, ground, fixed-site, naval, and handheld configurations. Frenel is a 2024 SPIE Prism Award recipient and an NVIDIA Inception Program member, and its technology is already in operational use in Israel. Wrap sees applicability extending well beyond counter-UAS — to defense ISR, autonomous vehicles, maritime domain awareness, border security, and critical-infrastructure protection.

Leadership and Financials

Founded roughly a decade ago, Wrap is led by Founder, Chairman, and CEO Scot Cohen, whose background spans more than two decades in asset management, wealth management, and capital markets, alongside President and Chief Operating Officer Jared Novick, who joined as COO in January 2024 and was promoted to President and COO in March 2025. The company is headquartered in Miami, Florida, with manufacturing operations in Southwestern Virginia. For fiscal year 2025, Wrap reported gross revenue growth of 15% to $5.2 million, driven by strong second-half momentum, and management has set a target of 100% revenue growth for 2026.

As agencies worldwide weigh how to reduce use-of-force incidents while keeping officers and the public safe, companies offering integrated restraint, training and evidence-management solutions are certain to remain part of that conversation. With a portfolio spanning the BolaWrap remote restraint device, the Wrap Reality and Wrap Tactics training platforms, the Wrap Vision evidence-management system, and its emerging counter-UAS programs, Wrap Technologies is positioning itself at the center of that shift toward integrated, non-lethal response.

For more information, visit the company’s website at Wrap.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• China accounts for around 60% of global mined production of magnet rare earths, while demand for the REEs that go into electric motors, wind turbines and defense systems has doubled since 2015.
• Canamera Energy Metals reported assay results from its Turvolândia Ionic Clay Rare Earth Project in Minas Gerais, Brazil, expanding the project from four to seven drill-confirmed rare earth target areas.
• The company also announced an option agreement with Nemo Resources Inc. to acquire 100% interest in the Rare Earth Ridge rare earth and niobium project in northwestern Ontario.

Rare earth elements (“REEs”) have quietly become one of the most consequential material groups in the modern economy, powering everything from electric vehicle motors to fighter jet guidance systems. Their unique magnetic and conductive properties make them nearly impossible to substitute in high-performance applications, which is precisely why supply security has become a matter of national strategy rather than simple commodity sourcing. , Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is one of the junior explorers working to expand that supply outside of China, and the company recently reported new drill results confirming an expanded rare earth system at its flagship Brazilian project, alongside a separate deal to option a new rare earth and niobium project in Ontario.

The scale of the challenge these companies are addressing is significant. China accounts for around 60% of global mined production of magnet rare earths and more than 90% of global refining capacity, with its dominance even greater in downstream permanent magnet manufacturing. Demand for the magnet rare earths that go into electric motors, wind turbines and defense systems has already doubled since 2015 and is projected to grow more than 30% further by 2030.

That concentration has become a geopolitical flashpoint rather than a background statistic. New Chinese export controls introduced in 2025 required foreign companies to obtain licenses for products containing Chinese-sourced rare earth materials, a rule the IEA notes extends to energy, automotive, defense, semiconductor, aerospace and data center supply chains. S&P Global has reported that pricing premiums for rare earth magnet materials are likely to persist through 2026 and beyond as non-Chinese processing capacity remains constrained, even as demand from robotics, defense and AI infrastructure keeps climbing. 

Against that backdrop, Canamera’s two most recent announcements show a company methodically building out both its resource base and its project pipeline. Earlier this month, the company reported assay results from its Turvolândia Ionic Clay Rare Earth Project in Minas Gerais, Brazil, expanding the project from four to seven drill-confirmed rare earth target areas. The standout result came from the new Rose target, where hole TUV-AUG-070 returned eight meters grading 2,238 parts per million total rare earth oxide, including three meters at 3,776 ppm near the bottom of the hole.

That release also detailed results from the Marita target, where all three reported holes ended in mineralized material with grades increasing toward the base of each hole, a pattern consistent with the ionic adsorption clay deposit model in which rare earths concentrate in the lower weathering profile above bedrock. Company geologists noted that of the 77 holes with results received so far out of 124 drilled, 62% returned at least one sample above 750 ppm total rare earth oxide, with a peak reading of 6,431 ppm at the previously reported Cordis target. Forty-seven additional results remain pending, including 20 follow-up holes at the Linda target, suggesting the company still has a substantial data release ahead of it.

Just a few days later, Canamera announced a second and distinct piece of news: an option agreement with Nemo Resources Inc. to acquire 100% interest in the Rare Earth Ridge rare earth and niobium project in northwestern Ontario. The project covers roughly 7,320 hectares across two carbonatite intrusions, a geological setting the company describes as the world’s primary natural source of rare earth elements and niobium. Canamera can earn its interest through staged share issuances over four years and is not obligated to incur minimum exploration spending, giving it flexibility over how quickly it advances the ground.

Taken together, the two releases illustrate a company advancing on parallel tracks rather than depending on a single asset. Turvolândia is transitioning from early discovery into a broader, better-defined system with multiple named targets and a large batch of assay results still to come, while Rare Earth Ridge adds a fourth prospective rare earth and niobium project to Canamera’s Ontario portfolio at minimal upfront cost. That combination of resource expansion in Brazil and low-commitment optionality in Canada reflects a fairly disciplined approach to portfolio building in a sector where exploration risk is high and access to capital can be uneven. For a junior explorer, that kind of steady, incremental progress, confirmed by qualified persons under NI 43-101 standards and reported through public disclosure, is often a more reliable signal of direction than any single headline number.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology’s most persistent development challenges.
• Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform
• Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support patient stratification, trial design, and evidence generation

Cancer drug development has three persistent problems. Tumors evolve resistance to therapies that once worked. Clinical trials fail often and cost enormously, frequently because the right patients are hard to identify. And many promising drugs never reach patients because they are too toxic or too difficult to deliver. For years, researchers attacked these problems separately. A newer approach treats them as connected, combining novel biology, advanced drug delivery, and artificial intelligence into a single development strategy. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a company building at that intersection.

New Biology: Targeting DNA Repair Beyond PARP

Cancer treatments such as radiation and chemotherapy work by damaging tumor DNA. Cancer cells survive by repairing that damage, which is why DNA Damage Response (“DDR”) inhibitors have become one of oncology’s fastest-moving categories. PARP inhibitors opened the field, but newer targets are expanding it. Onco-Innovations focuses on Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. 

Researchers are investigating PNKP inhibition through two complementary mechanisms. It sensitizes cancer cells to radiation and DNA-damaging chemotherapies, and it may produce antitumor activity as a monotherapy through synthetic lethality, in tumors that already carry specific repair deficiencies such as PTEN or SHP-1 loss. In preclinical work, PNKP inhibition has shown activity across colorectal, lung, breast, prostate, and ovarian cancers, as well as lymphoma and leukemia. Company materials describe DDR inhibitors as more than $7 billion in global sales in 2025, with PNKP positioned as an emerging class distinct from PARP.

Better Delivery: Widening the Safety Window

New biology only helps if the drug reaches the tumor. Many DDR inhibitors have struggled with off-target toxicity or poor solubility that complicates dosing. Onco’s lead candidate, ONC010, addresses that directly. It pairs A83B4C63, a small-molecule PNKP inhibitor, with a polymer micelle carrier designed to solubilize the drug, extend its time in circulation, increase tumor accumulation, and limit exposure to healthy tissue. In this design, the nanoparticle is not packaging; it is part of the therapy. 

In animal studies, the formulation slowed tumor growth, improved survival, and showed a favorable toxicity profile while increasing sensitivity to radiation and certain chemotherapies. The same delivery platform is designed to carry other hydrophobic, hard-to-deliver drugs, which the company views as a broader pipeline opportunity.

Smarter Development: Causal AI for Patients and Trials

The third front is where a drug’s path to approval is decided. Oncology trials are among the most expensive and failure-prone in medicine, and better patient selection is one of the few levers shown to improve their odds. Onco-Innovations acquired Inka Health in 2025 and, with it, SynoGraph, a causal AI prototype platform the company says is being designed to integrate real-world data, clinical evidence, and molecular insights to model treatment outcomes, safety, adverse events, and clinical trial performance.

Because regulators and clinicians remain wary of opaque systems, the platform is intended to support more transparent, auditable reasoning than conventional black-box models. The intent is practical: identify which patients are most likely to respond, design trials around them, and generate supporting evidence. Through Inka Health, the company has announced research collaborations and initiatives involving organizations including AstraZeneca and GSK.

Where the Three Meet

Individually, each of these advances is meaningful. Their potential value lies in how they interact. A more selective DNA-repair target reaches the tumor through a delivery system built for it, while AI helps choose the patients most likely to benefit and shapes the trials that test them. That is the logic behind Onco-Innovations’ dual platform, uniting DDR-targeted therapeutics with AI-driven precision oncology, and it aims squarely at the cancers that resist conventional treatment. The approach is designed to reduce development risk and shorten timelines, though, as with any preclinical program, those benefits remain to be proven in the clinic.

Building Toward First-in-Human

Onco-Innovations are preclinical and advancing toward first-in-human studies. It is running IND-enabling work with contract partners including Dalton Pharma Services and Nucro-Technics, and has established an Australian subsidiary to support planned Phase I activity through that country’s regulatory pathway. The scientific bench behind the program includes researchers involved in foundational PNKP-inhibitor work and development of the nanoparticle delivery mechanism.

Cancer rarely yields to a single idea. The more durable progress tends to come from combining them, matching the right target to the right delivery system and the right patients. Whether Onco-Innovations converts that convergence into clinical success remains to be seen, but the strategy reflects where oncology drug development is increasingly headed.

For more information, visit https://oncoinnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF